Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MGN vs ABEO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MGN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

MGN Overall Winner 6-Pillar Tally: MGN 4 – 2 ABEO Matrix Metrics: MGN 5 – 5 ABEO

As of Nov 16, 2026, Megan Holdings Limited (MGN) is the stronger overall head-to-head candidate over Abeona Therapeutics Inc. (ABEO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MGN carries a Unified Composite Score of 45.2/100 (HOLD) at $3.53 (N/M Forward P/E, -7.8% operating margin), whereas ABEO carries 44.9/100 (HOLD) at $2.60 (18.7x Forward P/E, -186.1% operating margin).

  • Growth vs. Quality Trade-Off: MGN earns the overall head-to-head edge with a stronger Unified Composite Score (45.2/100 HOLD vs. ABEO 44.9/100 HOLD) and 21.11β · 158% Vol risk profile, whereas ABEO leads top-line expansion (+2745.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MGN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 56.2); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MGN vs ABEO
MGN NASDAQ Head-to-Head Winner
Megan Holdings Limited Ordinary Shares
Agricultural Prod-Livestock & Animal Specialties
$3.53
-1.94% 1D
Market Cap $58.4M
TTM Revenue $83M
Forward P/E N/M
Beta / 30D Vol 21.11β · 158% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 40.0 Fund 35.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (75.0% over 20 days), RSI 56
RSI-14: 56.2 · SMA20: $3.23 · SMA50: $2.91
ABEO NASDAQ
Abeona Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.60
+7.44% 1D
Market Cap $149.2M
TTM Revenue $39M
Forward P/E 18.7x
Beta / 30D Vol 0.60β · 149% Vol
Unified Composite Score
44.9 / 100 HOLD
Tech 60.0 Fund 52.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.5%), weak momentum, RSI 26
RSI-14: 26.2 · SMA20: $3.78 · SMA50: $4.63

6-Pillar Scorecard Institutional Category Breakdown (MGN 4 – 2 ABEO)

Columns: Metric · MGN · ABEO
1. Valuation Multiples ABEO
Forward P/E N/M 18.7x
Trailing P/E N/M 18.7x
PEG Ratio N/M N/M
EV / Revenue 0.7x 2.6x
2. Growth & Scale ABEO
Revenue Growth (YoY) -8.4% +2745.0%
Earnings Growth (YoY) -31.3% +0.0%
TTM Revenue (USD) $83M $39M
Market Cap $58.4M $149.2M
3. Profitability & Quality MGN
Gross Margin 0.8% -3.5%
Operating Margin -7.8% -186.1%
Net Profit Margin -8.3% -160.3%
Return on Equity (ROE) -12.6% -42.1%
4. Balance Sheet & Cash Flow MGN
Cash Generation (TTM) -$6.4M EBITDA -$66M
Cash Flow Margin -7.7% EBITDA Mgn N/A
Net Cash / Leverage $14.39 Book/Sh · -12.6% ROE $50M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MGN
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 165.8% (27th %ile)
Put/Call OI Skew N/A 0.19x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat MGN
OpEx & R&D Intensity 8.6% of Rev ($7.1M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Engineering & Construction Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MGN (5) vs ABEO (5)
Institutional Metric MGN ABEO Criterion Row Edge
Market Capitalization
Scale
$58.4M $149.2M Larger Scale ABEO
Trailing P/E Ratio
Valuation
N/M 18.7x Lower Multiple ABEO
Forward P/E Ratio
Valuation
N/M 18.7x Lower Multiple ABEO
Revenue Growth (YoY)
Growth
-8.4% +2745.0% Higher Growth ABEO
Operating Margin (TTM)
Profitability
-7.8% -186.1% Higher Margin MGN
Net Profit Margin
Profitability
-8.3% -160.3% Higher Margin MGN
Return on Equity (ROE)
Capital Efficiency
-12.6% -42.1% Higher ROE MGN
52-Week Range Position
Momentum
68% ($0–$5) 9% ($2–$8) Stronger Trend MGN
Beta / 30D Volatility
Risk Regime
21.11β · 158% Vol 0.60β · 149% Vol Lower Realized Risk ABEO
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 44.9 / 100 (HOLD) Higher Composite MGN
Trailing 12M Revenue (USD)
Operating Scale
$83M $39M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.8% -3.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.7x EV/Rev N/M PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.4M EBITDA ($14.39 Book/Sh · -12.6% ROE) -$66M ($50M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MGN +81.95 pp
MGN: +40.64% · ABEO: -41.31%
3M Horizon MGN +3468.67 pp
MGN: +3412.44% · ABEO: -56.23%
6M Horizon MGN +2215.46 pp
MGN: +2162.82% · ABEO: -52.64%
1Y Horizon MGN +163.22 pp
MGN: +120.62% · ABEO: -42.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MGN vs ABEO. Trailing 12-month operating profitability (MGN -7.8% vs ABEO -186.1%) and valuation multiples (MGN N/M vs ABEO 18.7x Forward P/E) are benchmarked directly in Pillar 4 below.

MGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$83M
Gross Margin0.8%
Op. Margin-7.8%
ROE / Fwd P/E-12.6% · N/M
ABEO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$39M
Gross Margin-3.5%
Op. Margin-186.1%
ROE / Fwd P/E-42.1% · 18.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABEO BREAKDOWN
67d in phase · OBV DISTRIBUTION
Current IV 165.8%
IV Percentile 27th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ABEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MGN Moat Profile Cyclical / Execution-Driven Positioning
Engineering & Construction Operator
Competes within the Engineering & Construction value chain with $58.4M market capitalization and -7.8% operating margin.
OpEx & R&D Reinvestment 8.6% of Rev ($7.1M)
90D Engineering Disclosures 0 Published
ABEO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $149.2M market capitalization and -186.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MGN vs ABEO Key Questions & Quantitative Answers

As of Nov 16, 2026, Megan Holdings Limited (MGN) is the stronger overall head-to-head candidate over Abeona Therapeutics Inc. (ABEO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MGN carries a Unified Composite Score of 45.2/100 (HOLD) at $3.53 (N/M Forward P/E, -7.8% operating margin), whereas ABEO carries 44.9/100 (HOLD) at $2.60 (18.7x Forward P/E, -186.1% operating margin). Growth vs. Quality Trade-Off: MGN earns the overall head-to-head edge with a stronger Unified Composite Score (45.2/100 HOLD vs. ABEO 44.9/100 HOLD) and 21.11β · 158% Vol risk profile, whereas ABEO leads top-line expansion (+2745.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MGN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 56.2); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABEO leads the Growth & Scale pillar: MGN posts -8.4% YoY revenue growth and -31.3% YoY earnings growth on $83M TTM revenue (0.8% gross margin, -7.8% operating margin), compared with ABEO at +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin). On trailing 12-month operating scale, MGN generates $83M in USD-normalized revenue versus $39M for ABEO. In operating R&D and SG&A reinvestment, MGN deploys 8.6% of Rev ($7.1M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABEO.

ABEO screens cheaper on headline valuation multiples. MGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-7.7% EBITDA margin), whereas ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MGN (-12.6% ROE) versus ABEO (-42.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (21.11β · 158% Vol realized risk). By comparison, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.